News | July 08, 2022
Evonik launches non-animal-derived collagen platform for medical device applications
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Subscribe To Our Newsletter & Stay Updated
